why choose us

300×250 Ad Slot

Drug FDA Status

Showing 10 of 144 result(s) (Page 1 of 15)
Drug Name: Voyxact

Active Ingredient: sibeprenlimab-szsi

Approval Date: 2025-11-25

Description: To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

Drug Name: Hyrnuo

Active Ingredient: sevabertinib

Approval Date: 2025-11-19

Description: To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

Drug Name: Redemplo

Active Ingredient: plozasiran

Approval Date: 2025-11-18

Description: To reduce triglycerides in adults with familial chylomicronemia syndrome

Drug Name: Komzifti

Active Ingredient: ziftomenib

Approval Date: 2025-11-13

Description: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

Drug Name: Kygevvi

Active Ingredient: doxecitine and doxribtimine

Approval Date: 2025-11-03

Description: To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

Drug Name: Lynkuet

Active Ingredient: elinzanetant

Approval Date: 2025-10-24

Description: To treat moderate-to-severe vasomotor symptoms due to menopause

Drug Name: Jascayd

Active Ingredient: nerandomilast

Approval Date: 2025-10-07

Description: To treat idiopathic pulmonary fibrosis

Drug Name: Rhapsido

Active Ingredient: remibrutinib

Approval Date: 2025-09-30

Description: To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

Drug Name: Inluriyo

Active Ingredient: imlunestrant

Approval Date: 2025-09-25

Description: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Drug Name: Palsonify

Active Ingredient: paltusotine

Approval Date: 2025-09-25

Description: To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

300×250 Ad Slot